Akanda (AKAN) Competitors $1.21 -0.04 (-3.20%) Closing price 03:59 PM EasternExtended Trading$1.25 +0.04 (+3.64%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. LIXT, RNAZ, MBRX, CELZ, SLXN, AIM, OMGA, APLM, CDIO, and BFRIShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Lixte Biotechnology (LIXT), TransCode Therapeutics (RNAZ), Moleculin Biotech (MBRX), Creative Medical Technology (CELZ), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), Omega Therapeutics (OMGA), Apollomics (APLM), Cardio Diagnostics (CDIO), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors Lixte Biotechnology TransCode Therapeutics Moleculin Biotech Creative Medical Technology Silexion Therapeutics AIM ImmunoTech Omega Therapeutics Apollomics Cardio Diagnostics Biofrontera Lixte Biotechnology (NASDAQ:LIXT) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Does the media favor LIXT or AKAN? In the previous week, Lixte Biotechnology had 1 more articles in the media than Akanda. MarketBeat recorded 2 mentions for Lixte Biotechnology and 1 mentions for Akanda. Akanda's average media sentiment score of 0.94 beat Lixte Biotechnology's score of 0.83 indicating that Akanda is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akanda 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, LIXT or AKAN? Lixte Biotechnology has higher earnings, but lower revenue than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLixte BiotechnologyN/AN/A-$3.59M-$1.45-2.80Akanda$840K2.06-$4.10MN/AN/A Do institutionals and insiders hold more shares of LIXT or AKAN? 5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by insiders. Comparatively, 20.4% of Akanda shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is LIXT or AKAN more profitable? Company Net Margins Return on Equity Return on Assets Lixte BiotechnologyN/A N/A -189.35% Akanda N/A N/A N/A Which has more risk and volatility, LIXT or AKAN? Lixte Biotechnology has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. SummaryAkanda beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E RatioN/A11.7121.0120.09Price / Sales2.0630.03433.8199.01Price / CashN/A22.3936.1658.27Price / Book0.403.578.125.65Net Income-$4.10M$235.43M$3.25B$257.91M7 Day Performance-11.68%-1.67%0.97%2.09%1 Month Performance-6.92%2.91%7.36%11.13%1 Year Performance-71.73%-16.44%31.31%18.40% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkanda0.8467 of 5 stars$1.21-3.2%N/A-72.9%$1.78M$840K0.00110LIXTLixte Biotechnology0.2798 of 5 stars$2.72+21.4%N/A+60.9%$7.29MN/A-1.884RNAZTransCode Therapeutics2.7943 of 5 stars$8.72+8.3%$280.00+3,111.0%-100.0%$7.26MN/A0.009MBRXMoleculin Biotech2.8568 of 5 stars$0.51+31.1%$4.00+684.8%-81.2%$7.20MN/A0.0020High Trading VolumeCELZCreative Medical Technology0.808 of 5 stars$2.73+2.8%N/A-28.4%$7.06M$10K-0.725News CoverageSLXNSilexion TherapeuticsN/A$0.81-1.1%$5.00+521.1%N/A$7.00MN/A0.00N/ANews CoverageAIMAIM ImmunoTech1.4731 of 5 stars$9.13+3.2%$275.00+2,912.0%-79.5%$6.98M$146K-19.4320Gap UpOMGAOmega TherapeuticsN/A$0.13-21.8%$8.50+6,700.0%N/A$6.92M$8.10M-0.09120Gap UpAPLMApollomics0.614 of 5 stars$6.27-2.7%N/A-71.7%$6.91MN/A0.0045Gap DownCDIOCardio Diagnostics3.3475 of 5 stars$3.95+4.2%$60.00+1,419.0%-71.8%$6.87M$19.90K0.001Positive NewsBFRIBiofrontera3.07 of 5 stars$0.73+4.5%$2.75+278.8%-26.0%$6.86M$38.00M-0.3270Positive NewsGap Up Related Companies and Tools Related Companies LIXT Competitors RNAZ Competitors MBRX Competitors CELZ Competitors SLXN Competitors AIM Competitors OMGA Competitors APLM Competitors CDIO Competitors BFRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKAN Stock Alerts